Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient

Hemoglobin

Volumn 31, Issue 4, 2007, Pages 499-501

  Sheikh Taha, Marwan ^a   Koussa, Suzane ^b   Inati, Adlette ^b   Taher, Ali ^b,c,d  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b Chronic Care Center Hazmieh   (Lebanon)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d American University of Beirut Medical Center ^*  (Lebanon)

Author keywords

Deferiprone (L1); Febrile neutropenia; Hemorrhagic stroke; Thalassemia major

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CEFEPIME; DEFERIPRONE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEICOPLANIN; VALPROIC ACID;

ADULT; AGRANULOCYTOSIS; ANAMNESIS; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD CULTURE; BLOOD TRANSFUSION; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEMORRHAGIC STROKE; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; SEIZURE; STROKE; THALASSEMIA MAJOR; THROAT CULTURE; TREATMENT OUTCOME; URINE CULTURE;

ADULT; AGRANULOCYTOSIS; BETA-THALASSEMIA; BLOOD TRANSFUSION; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; IRON CHELATING AGENTS; NEUTROPENIA; PYRIDONES; SPLENECTOMY;

EID: 36248991398     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701641211     Document Type: Article

References (5)

1. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91(1):224-229.
2. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118(1):330-336.
3. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102(5):1583-1587.
4. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992; 80(3):593-599.
5. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. Br Med J 1999; 318(7186):759-764.